Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Can Coronavirus Disease 2019 (Covid-19) Trigger Exacerbation of Multiple Sclerosis? a Retrospective Study Publisher Pubmed



Barzegar M1, 2 ; Vaheb S2, 3 ; Mirmosayyeb O1, 2 ; Afsharisafavi A2, 4 ; Nehzat N2 ; Shaygannejad V1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Student Research Committee, Faculty of Paramedicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran

Source: Multiple Sclerosis and Related Disorders Published:2021


Abstract

The effect of coronavirus disease (COVID-19) on the risk of relapse in multiple sclerosis (MS) have been unknown. In this retrospective study of 41 relapsing-remitting MS patients, number of relapses in pre-defined at risk-period (ARP) was compared with the previous two years. During the previous two years, a total of 32 attacks was reported, which 5 (15.6%) were during the at-risk period. After adjusting for age and sex, there was an increased risk of attack during ARP compared to the previous two years (RR: 2.566, 95%CI: 1.075-6.124, P=0.034). Our preliminary study suggested that COVID-19 can trigger exacerbation of MS. © 2021
Related Docs
View other Related Docs
1. Covid-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight With No Bystander Effect?, Multiple Sclerosis and Related Disorders (2021)
2. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
3. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic, Biomolecules (2021)
4. Covid-19 Among Patients With Multiple Sclerosis a Systematic Review, Neurology: Neuroimmunology and NeuroInflammation (2021)
5. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
6. Does Covid-19 Increase the Long-Term Relapsing-Remitting Multiple Sclerosis Clinical Activity? a Cohort Study, BMC Neurology (2022)
7. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)
8. Covid-19 Infection and Hospitalization Rate in Iranian Multiple Sclerosis Patients: What We Know by May 2021, Multiple Sclerosis and Related Disorders (2022)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (77)
Masoud Etemadifar (63)
Other Related Docs
9. Seasonal and Monthly Variation in Multiple Sclerosis Relapses: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2022)
10. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of Covid-19 in Multiple Sclerosis: A Menactrims Registry Based Study, Multiple Sclerosis and Related Disorders (2024)
11. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
12. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
13. Impact of the Covid-19 Pandemic on the Psychological Status and Cortisol Level of Multiple Sclerosis Patients, Neuropsychological Rehabilitation (2023)
14. Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis, Neurology Research International (2021)
15. Early Predictors of Conversion to Secondary Progressive Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2021)
16. Prevalence and Risk Factors of Dysphagia in Patients With Multiple Sclerosis, Dysphagia (2022)
17. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
18. Self-Reported Safety of the Bbibp-Corv (Sinopharm) Covid-19 Vaccine Among Iranian People With Multiple Sclerosis, Human Vaccines and Immunotherapeutics (2022)
19. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
20. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)
21. Fear and Anxiety in Patients With Multiple Sclerosis During Covid-19 Pandemic; Report of an Iranian Population, Multiple Sclerosis and Related Disorders (2021)
22. Cns Demyelinating Disease Following Inactivated or Viral Vector Sars-Cov-2 Vaccines: A Case Series, Vaccine (2023)
23. Lateonset Multiple Sclerosis in Isfahan, Iran, Archives of Iranian Medicine (2012)
24. Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy, European Neurology (2012)
25. Insights Into the Interplay Between Epstein-Barr Virus (Ebv) and Multiple Sclerosis (Ms): A State-Of-The-Art Review and Implications for Vaccine Development, Health Science Reports (2024)
26. Bremso: A Simple Score to Predict Early the Natural Course of Multiple Sclerosis, European Journal of Neurology (2015)
27. A Case-Control Study on Risk Factors in Pediatric Multiple Sclerosis Population, Isfahan Province, Iran: Highlighting the Role of Puberty, Journal of Isfahan Medical School (2017)
28. Variability of the Response to Immunotherapy Among Subgroups of Patients With Multiple Sclerosis, European Journal of Neurology (2023)
29. Examining the Environmental Risk Factors of Progressive-Onset and Relapsing-Onset Multiple Sclerosis: Recruitment Challenges, Potential Bias, and Statistical Strategies, Journal of Neurology (2024)
30. Risk Factors of Early Onset of Ms in Women in Reproductive Age Period: Survival Analysis Approach, Archives of Women's Mental Health (2016)
31. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
32. Can Coronavirus Disease 2019 (Covid-19) Trigger Exacerbation of Multiple Sclerosis? a Retrospective Study, Multiple Sclerosis and Related Disorders (2021)
33. Atherosclerosis and Multiple Sclerosis: An Overview on the Prevalence of Risk Factors, Multiple Sclerosis and Related Disorders (2022)
34. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis, Neurotherapeutics (2025)
35. Male Sex Is Independently Associated With Faster Disability Accumulation in Relapse-Onset Ms But Not in Primary Progressive Ms, PLoS ONE (2015)
36. Stress Differentially Predicts Multiple Sclerosis Relapses, Neurology Asia (2014)
37. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
38. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
39. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
40. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
41. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)
42. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
43. Outcome of Covid-19 Infection in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies, Journal of Research in Medical Sciences (2021)
44. Risk Factors of Multiple Sclerosis and Their Relation With Disease Severity: A Cross-Sectional Study From Iran, Archives of Iranian Medicine (2016)
45. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis, JAMA Neurology (2018)
46. Sex As a Determinant of Relapse Incidence and Progressive Course of Multiple Sclerosis, Brain (2013)
47. Prevalence of Trigeminal Neuralgia in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
48. The Global Prevalence of Familial Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis, BMC Neurology (2021)
49. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
50. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)